These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23664229)

  • 21. Polymyxin B-immobilized fiber hemoperfusion after emergency surgery in patients with chronic renal failure.
    Tojimbara T; Sato S; Nakajima I; Fuchinoue S; Akiba T; Teraoka S
    Ther Apher Dial; 2004 Aug; 8(4):286-92. PubMed ID: 15274679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New therapeutic strategies in severe sepsis and septic shock].
    Oddo M; Schaller MD; Calandra T; Liaudet L
    Rev Med Suisse Romande; 2004 Jun; 124(6):329-32. PubMed ID: 15293439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical points for sepsis management at the patient bedside.
    Tulli G
    Minerva Anestesiol; 2003; 69(1-2):35-56, 56-65. PubMed ID: 12677162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.
    Jarczak D; Kluge S; Nierhaus A
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sepsis and organ failure--its pathogenesis and treatment].
    Hanasawa K; Kodama M
    Nihon Geka Gakkai Zasshi; 1998 Aug; 99(8):523-7. PubMed ID: 9789288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in plasma interleukin-18 by direct hemoperfusion with polymyxin B-immobilized fiber in patients with septic shock.
    Nakamura T; Kawagoe Y; Suzuki T; Shoji H; Ueda Y; Kobayashi N; Koide H
    Blood Purif; 2005; 23(6):417-20. PubMed ID: 16141713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is neuroimmunomodulation a future therapeutic approach for sepsis?
    Kumar V; Sharma A
    Int Immunopharmacol; 2010 Jan; 10(1):9-17. PubMed ID: 19840870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effects of use polymyxin B fixed on fibers in liver transplant patients with severe sepsis or septic shock.
    Ruberto F; Pugliese F; D'Alio A; Martelli S; Bruno K; Marcellino V; Perrella S; Cappannoli A; Mazzarino V; Tosi A; Novelli G; Rossi M; Ginanni Corradini S; Ferretti G; Berloco PB; Pietropaoli P
    Transplant Proc; 2007; 39(6):1953-5. PubMed ID: 17692664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber.
    Ono S; Tsujimoto H; Matsumoto A; Ikuta S; Kinoshita M; Mochizuki H
    Am J Surg; 2004 Aug; 188(2):150-6. PubMed ID: 15249240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacotherapy of sepsis].
    Guzzo I; Morabito S; Stucchi R; Poli G; Fumagalli R
    G Ital Nefrol; 2006; 23 Suppl 36():S79-86. PubMed ID: 17068734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging drugs for the treatment of sepsis.
    Heming N; Lamothe L; Ambrosi X; Annane D
    Expert Opin Emerg Drugs; 2016; 21(1):27-37. PubMed ID: 26751198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversies in neonatal sepsis: immunomodulation in the treatment and prevention of neonatal sepsis.
    Moss SJ; Gennery AR
    Adv Exp Med Biol; 2006; 582():71-83. PubMed ID: 16802620
    [No Abstract]   [Full Text] [Related]  

  • 33. A defining time for sepsis.
    Pettigrew CA
    Trends Mol Med; 2014 Apr; 20(4):191. PubMed ID: 24698493
    [No Abstract]   [Full Text] [Related]  

  • 34. What's new in the quagmire of sepsis?
    Ward PA
    Trends Mol Med; 2014 Apr; 20(4):189-90. PubMed ID: 24698492
    [No Abstract]   [Full Text] [Related]  

  • 35. [The current trends in the development of new immunobiological preparations].
    Vorob'ev AA
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (5):16-21. PubMed ID: 10852017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Do biologicals have a place in the treatment of collagen diseases? Contra].
    Fleck M
    Dtsch Med Wochenschr; 2009 Sep; 134(36):1765. PubMed ID: 19718599
    [No Abstract]   [Full Text] [Related]  

  • 37. Updates on role of human recombinant activated protein C in patients with sepsis and severe sepsis: Changed scenario after PROWESS SHOCK trial.
    Shukla A
    Indian J Anaesth; 2012 Nov; 56(6):597-8. PubMed ID: 23325958
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune dysregulation in sepsis: experiences, lessons and perspectives.
    Cao M; Wang G; Xie J
    Cell Death Discov; 2023 Dec; 9(1):465. PubMed ID: 38114466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal Timing and Early Intervention With Anticoagulant Therapy for Sepsis-Induced Disseminated Intravascular Coagulation.
    Yamakawa K; Umemura Y; Murao S; Hayakawa M; Fujimi S
    Clin Appl Thromb Hemost; 2019; 25():1076029619835055. PubMed ID: 30841721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole-organism phenotypic screening for anti-infectives promoting host health.
    Clatworthy AE; Romano KP; Hung DT
    Nat Chem Biol; 2018 Apr; 14(4):331-341. PubMed ID: 29556098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.